Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Rubio-Rivas

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Autoimmunity Reviews|March 21, 2020
Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validationManuel Rubio-Rivas, Xavier Corbella, Alfredo Guillén-Del-Castillo, et al.
Autoimmunity Reviews|August 5, 2022
Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)Cristina Carbonell, Miguel Marcos, Alfredo Guillén-Del-Castillo, et al.
Rheumatology (Oxford, England)|August 12, 2025
Decreasing prevalence and cumulative incidence of scleroderma renal crisis over time: associated factors identified from the RESCLE registryXavier Pla-Salas, Carles Tolosa-Vilella, Maria Baldà-Masmiquel, et al.
Clinical Rheumatology|December 8, 2017
First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort studyManuel Rubio-Rivas, Xavier Corbella, Melany Pestaña-Fernández, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Autoimmunity Reviews|March 21, 2020
Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validationManuel Rubio-Rivas, Xavier Corbella, Alfredo Guillén-Del-Castillo, et al.
Autoimmunity Reviews|August 5, 2022
Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)Cristina Carbonell, Miguel Marcos, Alfredo Guillén-Del-Castillo, et al.
Rheumatology (Oxford, England)|August 12, 2025
Decreasing prevalence and cumulative incidence of scleroderma renal crisis over time: associated factors identified from the RESCLE registryXavier Pla-Salas, Carles Tolosa-Vilella, Maria Baldà-Masmiquel, et al.
Clinical Rheumatology|December 8, 2017
First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort studyManuel Rubio-Rivas, Xavier Corbella, Melany Pestaña-Fernández, et al.
Pageof 9